Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

209 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Targeting DDX3 with a small molecule inhibitor for lung cancer therapy.
Bol GM, Vesuna F, Xie M, Zeng J, Aziz K, Gandhi N, Levine A, Irving A, Korz D, Tantravedi S, Heerma van Voss MR, Gabrielson K, Bordt EA, Polster BM, Cope L, van der Groep P, Kondaskar A, Rudek MA, Hosmane RS, van der Wall E, van Diest PJ, Tran PT, Raman V. Bol GM, et al. Among authors: rudek ma. EMBO Mol Med. 2015 May;7(5):648-69. doi: 10.15252/emmm.201404368. EMBO Mol Med. 2015. PMID: 25820276 Free PMC article.
Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer.
Juergens RA, Wrangle J, Vendetti FP, Murphy SC, Zhao M, Coleman B, Sebree R, Rodgers K, Hooker CM, Franco N, Lee B, Tsai S, Delgado IE, Rudek MA, Belinsky SA, Herman JG, Baylin SB, Brock MV, Rudin CM. Juergens RA, et al. Among authors: rudek ma. Cancer Discov. 2011 Dec;1(7):598-607. doi: 10.1158/2159-8290.CD-11-0214. Epub 2011 Nov 9. Cancer Discov. 2011. PMID: 22586682 Free PMC article. Clinical Trial.
Successful gene therapy requires targeting the vast majority of cancer cells.
Sagara T, Debeljak M, Wright CM, Anders NM, Liang H, Rudek MA, Ostermeier M, Eshleman JR, Matsushita Y. Sagara T, et al. Among authors: rudek ma. Cancer Biol Ther. 2020 Oct 2;21(10):946-953. doi: 10.1080/15384047.2020.1809912. Epub 2020 Sep 30. Cancer Biol Ther. 2020. PMID: 32997949 Free PMC article.
Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study.
Hammers HJ, Verheul HM, Salumbides B, Sharma R, Rudek M, Jaspers J, Shah P, Ellis L, Shen L, Paesante S, Dykema K, Furge K, Teh BT, Netto G, Pili R. Hammers HJ, et al. Mol Cancer Ther. 2010 Jun;9(6):1525-35. doi: 10.1158/1535-7163.MCT-09-1106. Epub 2010 May 25. Mol Cancer Ther. 2010. PMID: 20501804 Free PMC article.
A polymeric nanoparticle encapsulated small-molecule inhibitor of Hedgehog signaling (NanoHHI) bypasses secondary mutational resistance to Smoothened antagonists.
Chenna V, Hu C, Pramanik D, Aftab BT, Karikari C, Campbell NR, Hong SM, Zhao M, Rudek MA, Khan SR, Rudin CM, Maitra A. Chenna V, et al. Among authors: rudek ma. Mol Cancer Ther. 2012 Jan;11(1):165-73. doi: 10.1158/1535-7163.MCT-11-0341. Epub 2011 Oct 25. Mol Cancer Ther. 2012. PMID: 22027695 Free PMC article.
A phase 1/pharmacokinetic study of sunitinib in combination with highly active antiretroviral therapy in human immunodeficiency virus-positive patients with cancer: AIDS Malignancy Consortium trial AMC 061.
Rudek MA, Moore PC, Mitsuyasu RT, Dezube BJ, Aboulafia D, Gerecitano J, Sullivan R, Cianfrocca ME, Henry DH, Ratner L, Haigentz M Jr, Dowlati A, Little RF, Ivy SP, Deeken JF. Rudek MA, et al. Cancer. 2014 Apr 15;120(8):1194-202. doi: 10.1002/cncr.28554. Epub 2014 Jan 28. Cancer. 2014. PMID: 24474568 Free PMC article. Clinical Trial.
209 results